Understanding clinical outcomes and factors influencing mortality in intensive care unit patients with COVID-19-associated candidemia
© 2024 The Authors. Mycoses published by Wiley-VCH GmbH..
BACKGROUND: During the COVID pandemic, research has shown an increase in candidemia cases following severe COVID infection and the identification of risk factors associated with candidemia. However, there is a lack of studies that specifically explore clinical outcomes and mortality rates related to candidemia after COVID infection.
OBJECTIVES: The aim of this international study was to evaluate the clinical outcomes and identify factors influencing mortality in patients who developed candidemia during their COVID infection.
PATIENTS/METHODS: This study included adult patients (18 years of age or older) admitted to the intensive care unit (ICU) and diagnosed with COVID-associated candidemia (CAC). The research was conducted through ID-IRI network and in collaboration with 34 medical centres across 18 countries retrospectively, spanning from the beginning of the COVID pandemic until December 2021.
RESULTS: A total of 293 patients diagnosed with CAC were included. The median age of the patients was 67, and 63% of them were male. The most common Candida species detected was C. albicans. The crude 30-day mortality rate was recorded at 62.4%. The logistic regression analysis identified several factors significantly impacting mortality, including age (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.02-1.07, p < .0005), SOFA score (OR 1.307, 95% CI 1.17-1.45, p < .0005), invasive mechanical ventilation (OR 7.95, 95% CI 1.44-43.83, p < .017) and duration of mechanical ventilation (OR 0.98, 95% CI 0.96-0.99, p < .020).
CONCLUSIONS: By recognising these prognostic factors, medical professionals can customise their treatment approaches to offer more targeted care, leading to improved patient outcomes and higher survival rates for individuals with COVID-associated candidemia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Mycoses - 67(2024), 1 vom: 29. Jan., Seite e13687 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 29.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/myc.13687 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367049775 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367049775 | ||
| 003 | DE-627 | ||
| 005 | 20240129232059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/myc.13687 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1274.xml |
| 035 | |a (DE-627)NLM367049775 | ||
| 035 | |a (NLM)38214425 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aydın, Selda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Understanding clinical outcomes and factors influencing mortality in intensive care unit patients with COVID-19-associated candidemia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 29.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Mycoses published by Wiley-VCH GmbH. | ||
| 520 | |a BACKGROUND: During the COVID pandemic, research has shown an increase in candidemia cases following severe COVID infection and the identification of risk factors associated with candidemia. However, there is a lack of studies that specifically explore clinical outcomes and mortality rates related to candidemia after COVID infection | ||
| 520 | |a OBJECTIVES: The aim of this international study was to evaluate the clinical outcomes and identify factors influencing mortality in patients who developed candidemia during their COVID infection | ||
| 520 | |a PATIENTS/METHODS: This study included adult patients (18 years of age or older) admitted to the intensive care unit (ICU) and diagnosed with COVID-associated candidemia (CAC). The research was conducted through ID-IRI network and in collaboration with 34 medical centres across 18 countries retrospectively, spanning from the beginning of the COVID pandemic until December 2021 | ||
| 520 | |a RESULTS: A total of 293 patients diagnosed with CAC were included. The median age of the patients was 67, and 63% of them were male. The most common Candida species detected was C. albicans. The crude 30-day mortality rate was recorded at 62.4%. The logistic regression analysis identified several factors significantly impacting mortality, including age (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.02-1.07, p < .0005), SOFA score (OR 1.307, 95% CI 1.17-1.45, p < .0005), invasive mechanical ventilation (OR 7.95, 95% CI 1.44-43.83, p < .017) and duration of mechanical ventilation (OR 0.98, 95% CI 0.96-0.99, p < .020) | ||
| 520 | |a CONCLUSIONS: By recognising these prognostic factors, medical professionals can customise their treatment approaches to offer more targeted care, leading to improved patient outcomes and higher survival rates for individuals with COVID-associated candidemia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19-associated candidemia | |
| 650 | 4 | |a candidemia | |
| 650 | 4 | |a intensive care unit | |
| 650 | 4 | |a mortality | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Mert, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Yılmaz, Mesut |e verfasserin |4 aut | |
| 700 | 1 | |a Al Maslamani, Muna |e verfasserin |4 aut | |
| 700 | 1 | |a Rahimi, Bilal Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Ayoade, Folusakin |e verfasserin |4 aut | |
| 700 | 1 | |a El-Kholy, Amani |e verfasserin |4 aut | |
| 700 | 1 | |a Belitova, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Sengel, Buket Erturk |e verfasserin |4 aut | |
| 700 | 1 | |a Jalal, Sabah |e verfasserin |4 aut | |
| 700 | 1 | |a Albayrak, Ayşe |e verfasserin |4 aut | |
| 700 | 1 | |a Alatawi, Jamayel Adnan |e verfasserin |4 aut | |
| 700 | 1 | |a Szabo, Balint Gergely |e verfasserin |4 aut | |
| 700 | 1 | |a Ganeshan, Ramesh Shankar |e verfasserin |4 aut | |
| 700 | 1 | |a Nsutebu, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Poojary, Aruna |e verfasserin |4 aut | |
| 700 | 1 | |a Akkoyunlu, Yasemin |e verfasserin |4 aut | |
| 700 | 1 | |a Alkan, Sevil |e verfasserin |4 aut | |
| 700 | 1 | |a Elik, Dilşah Başkol |e verfasserin |4 aut | |
| 700 | 1 | |a Eser-Karlidag, Gulden |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Lurdes |e verfasserin |4 aut | |
| 700 | 1 | |a Moroti, Ruxandra |e verfasserin |4 aut | |
| 700 | 1 | |a Altın, Nilgün |e verfasserin |4 aut | |
| 700 | 1 | |a Gürbüz, Esra |e verfasserin |4 aut | |
| 700 | 1 | |a Ulusoy, Tülay Ünver |e verfasserin |4 aut | |
| 700 | 1 | |a Sipahi, Oğuz Reşat |e verfasserin |4 aut | |
| 700 | 1 | |a Çaşkurlu, Hülya |e verfasserin |4 aut | |
| 700 | 1 | |a Esmaoğlu, Aliye |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, Botond |e verfasserin |4 aut | |
| 700 | 1 | |a El-Sayed, Nagwa Mostafa |e verfasserin |4 aut | |
| 700 | 1 | |a Marıno, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cascio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Mihai, Alexandru |e verfasserin |4 aut | |
| 700 | 1 | |a Dumitru, Irina Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Pshenichnaya, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Ripon, Rezaul Karim |e verfasserin |4 aut | |
| 700 | 1 | |a Makek, Mateja Jankovic |e verfasserin |4 aut | |
| 700 | 1 | |a Rashid, Naveed |e verfasserin |4 aut | |
| 700 | 1 | |a Baljić, Rusmir |e verfasserin |4 aut | |
| 700 | 1 | |a Dascalu, Cosmin |e verfasserin |4 aut | |
| 700 | 1 | |a Sincan, Gülden |e verfasserin |4 aut | |
| 700 | 1 | |a Kızmaz, Yeşim Uygun |e verfasserin |4 aut | |
| 700 | 1 | |a Madendere, Berk |e verfasserin |4 aut | |
| 700 | 1 | |a Erdem, Hakan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mycoses |d 1990 |g 67(2024), 1 vom: 29. Jan., Seite e13687 |w (DE-627)NLM01265194X |x 1439-0507 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2024 |g number:1 |g day:29 |g month:01 |g pages:e13687 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/myc.13687 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2024 |e 1 |b 29 |c 01 |h e13687 | ||